189,900 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC acquired a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 189,900 shares of the company’s stock, valued at approximately $14,776,000. TimesSquare Capital Management LLC owned 0.26% of Kymera Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in KYMR. Vanguard Group Inc. lifted its stake in Kymera Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after purchasing an additional 845,922 shares in the last quarter. Holocene Advisors LP acquired a new position in Kymera Therapeutics during the third quarter worth $47,563,000. Commodore Capital LP acquired a new position in Kymera Therapeutics during the second quarter worth $32,730,000. Alyeska Investment Group L.P. lifted its stake in Kymera Therapeutics by 1,130.2% during the third quarter. Alyeska Investment Group L.P. now owns 615,091 shares of the company’s stock worth $34,814,000 after purchasing an additional 565,091 shares in the last quarter. Finally, Federated Hermes Inc. acquired a new position in Kymera Therapeutics during the third quarter worth $31,622,000.

Analyst Upgrades and Downgrades

KYMR has been the topic of a number of research reports. Canaccord Genuity Group initiated coverage on Kymera Therapeutics in a research note on Wednesday, May 6th. They set a “buy” rating and a $106.00 price target on the stock. Citigroup upped their price target on Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Wall Street Zen upgraded Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Royal Bank Of Canada restated an “outperform” rating and set a $108.00 price target on shares of Kymera Therapeutics in a research note on Thursday, February 26th. Finally, Piper Sandler upped their price target on Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Kymera Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $118.10.

Insider Buying and Selling

In other Kymera Therapeutics news, COO Jeremy G. Chadwick sold 300 shares of the firm’s stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $90.00, for a total value of $27,000.00. Following the sale, the chief operating officer directly owned 61,202 shares in the company, valued at $5,508,180. This trade represents a 0.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Elena Ridloff sold 3,000 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $87.00, for a total value of $261,000.00. Following the completion of the sale, the director owned 3,000 shares in the company, valued at approximately $261,000. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 383,734 shares of company stock valued at $32,454,902 over the last 90 days. 15.98% of the stock is currently owned by corporate insiders.

Kymera Therapeutics Price Performance

Kymera Therapeutics stock opened at $78.14 on Wednesday. Kymera Therapeutics, Inc. has a 1-year low of $28.06 and a 1-year high of $103.00. The stock has a market cap of $6.43 billion, a PE ratio of -21.89 and a beta of 2.06. The stock’s fifty day moving average is $83.40 and its two-hundred day moving average is $78.31.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The company had revenue of $34.37 million for the quarter, compared to analysts’ expectations of $8.27 million. During the same period last year, the firm earned ($0.82) earnings per share. Kymera Therapeutics’s quarterly revenue was up 55.5% on a year-over-year basis. On average, research analysts expect that Kymera Therapeutics, Inc. will post -3.34 earnings per share for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.